Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.21.2
Commitments and Contingencies - Additional Information (Detail)
9 Months Ended
Mar. 12, 2021
Jan. 15, 2021
Sep. 30, 2021
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuit Filing Date   January 15, 2021  
Loss Contingency, Name of Plaintiff   Genfit S.A.  
Loss Contingency, Allegations   alleging misappropriation of trade secrets and related causes of action based on the Company’s receipt of a Genfit protocol synopsis for Genfit’s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis.  
Loss Contingency, Actions Taken by Defendant   The Company intends to defend itself vigorously. While the outcome of any litigation is inherently uncertain, based on currently available information, management does not currently believe a loss associated with this matter is probable, nor is any amount reasonably estimable  
Loss Contingency, Actions Taken by Court, Arbitrator or Mediator On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto.    
Pending Litigation [Member]      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuit Filing Date     April 16, 2021